Biomerica, Inc. (BMRA) Key Metrics
BMRA valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $8.5M
- Enterprise value
- $13.0M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 1.9 10-yr median 28.9
- Price / book
- 4.5 10-yr median 37.1
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.38
BMRA key metrics, FY2017–FY2026
Fiscal year ended May 31, 2026 · U.S. dollarsBMRA valuation Price multiples at each fiscal year-end price.
Price / sales+18.6%
1.6
FY2026 · hover or tap a bar for each year
FY2017FY2026
Price / book+55.2%
2.6
FY2026 · hover or tap a bar for each year
FY2017FY2026
Free cash flow yield+6.2 pts
−49.1%
FY2026 · hover or tap a bar for each year
FY2017FY2026
BMRA returns How much profit the business earns on the capital it uses.
Return on equity−19.1 pts
−112.1%
FY2026 · hover or tap a bar for each year
FY2017FY2026
Return on invested capital+7.9 pts
−143.2%
FY2026 · hover or tap a bar for each year
FY2017FY2026
Return on assets+6.0 pts
−59.4%
FY2026 · hover or tap a bar for each year
FY2017FY2026
Free cash flow margin−3.8 pts
−76.8%
FY2026 · hover or tap a bar for each year
FY2017FY2026
Asset turnover+0.3%
0.70
FY2026 · hover or tap a bar for each year
FY2017FY2026
BMRA per-share figures Results divided by the shares outstanding at year-end.
Revenue per share−33.9%
$1.53
FY2026 · hover or tap a bar for each year
FY2017FY2026
Earnings per share
−$1.30
FY2026 · hover or tap a bar for each year
FY2017FY2026
Free cash flow per share
−$1.17
FY2026 · hover or tap a bar for each year
FY2017FY2026
Book value per share−49.5%
$0.90
FY2026 · hover or tap a bar for each year
FY2017FY2026
Shares outstanding+26.9%
2.9M
FY2026 · hover or tap a bar for each year
FY2017FY2026
BMRA financial health Debt, liquidity and how easily interest is covered.
Debt / equity+712.1%
0.91
FY2026 · hover or tap a bar for each year
FY2017FY2026
Net debt+$3.0M
$1.1M
FY2026 · hover or tap a bar for each year
FY2017FY2026
Current ratio−42.2%
1.62
FY2026 · hover or tap a bar for each year
FY2017FY2026
Debt / assets+357.6%
0.35
FY2026 · hover or tap a bar for each year
FY2017FY2026
BMRA efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding+4 days
62 days
FY2026 · hover or tap a bar for each year
FY2017FY2026
Days of inventory−4 days
143 days
FY2026 · hover or tap a bar for each year
FY2017FY2026
Days payables outstanding+8 days
30 days
FY2026 · hover or tap a bar for each year
FY2017FY2026
Cash conversion cycle−7 days
175 days
FY2026 · hover or tap a bar for each year
FY2017FY2026
Capex / revenue−0.7 pts
0.0%
FY2026 · hover or tap a bar for each year
FY2017FY2026
BMRA valuation history
Fiscal year-endToday10-year median
BMRA returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
BMRA debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
BMRA cash returned to shareholders
DividendsBuybacksFree cash flow
BMRA price vs earnings per share
Share price at year-endEPS (right axis)
BMRA key metrics
FY2017–FY2026| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $7.0M | $7.0M | $78.1M | $155.1M | $354.9M | $348.3M | $526.2M | $165.8M | $279.0M | $166.6M |
| Enterprise value | $8.0M | $5.1M | $74.7M | $146.5M | $350.3M | $345.7M | $519.3M | $165.1M | $277.8M | $165.4M |
| Price / sales | 1.6 | 1.3 | 14.4 | 29.1 | 18.8 | 48.4 | 78.6 | 31.9 | 50.1 | 28.8 |
| Price / book | 2.6 | 1.7 | 11.8 | 13.2 | 42.6 | 37.8 | 37.0 | 41.7 | 64.5 | 37.1 |
| EV / sales | 1.8 | 1.0 | 13.8 | 27.4 | 18.6 | 48.0 | 77.6 | 31.8 | 49.9 | 28.6 |
| Earnings yield | −54.2% | −71.0% | −7.7% | −4.6% | −1.3% | −2.1% | −0.4% | −1.4% | −0.5% | −0.5% |
| Free cash flow yield | −49.1% | −55.4% | −7.0% | −3.6% | −0.2% | −1.6% | −0.8% | −1.5% | −0.5% | −0.5% |
| Dividend yield | — | — | — | — | — | — | — | — | 0.0% | 0.0% |
| Shareholder yield (dividends + buybacks) | — | — | 0.0% | 0.5% | 0.0% | 0.0% | — | 0.0% | 0.0% | 0.0% |
| Share price at fiscal year-end | $2.39 | $3.05 | $4.64 | $10.96 | $28.00 | $29.20 | $51.76 | $18.00 | $32.56 | $20.00 |
| Per share | ||||||||||
| Revenue per share | $1.53 | $2.31 | $0.32 | $0.38 | $1.49 | $0.60 | $0.66 | $0.56 | $0.65 | $0.70 |
| Earnings per share | −$1.30 | −$2.16 | −$0.36 | −$0.50 | −$0.36 | −$0.62 | −$0.23 | −$0.26 | −$0.17 | −$0.11 |
| Operating cash flow per share | −$1.17 | −$1.67 | −$0.32 | −$0.39 | −$0.04 | −$0.44 | −$0.42 | −$0.24 | −$0.14 | −$0.09 |
| Free cash flow per share | −$1.17 | −$1.69 | −$0.33 | −$0.39 | −$0.05 | −$0.47 | −$0.43 | −$0.26 | −$0.15 | −$0.10 |
| Cash per share | $0.45 | $1.04 | $0.25 | $0.69 | $0.47 | $0.35 | $0.85 | $0.07 | $0.14 | $0.15 |
| Book value per share | $0.90 | $1.79 | $0.39 | $0.83 | $0.66 | $0.77 | $1.40 | $0.43 | $0.50 | $0.54 |
| Tangible book value per share | $0.83 | $1.69 | $0.38 | $0.82 | $0.64 | $0.75 | $1.38 | $0.42 | $0.49 | $0.52 |
| Dividends per share | — | — | — | — | — | — | — | — | $0.00 | $0.00 |
| Capex per share | $0.00 | $0.02 | $0.01 | $0.01 | $0.01 | $0.02 | $0.01 | $0.02 | $0.02 | $0.01 |
| Debt per share | $0.82 | $0.20 | $0.05 | $0.08 | $0.11 | $0.14 | $0.18 | — | $0.00 | $0.00 |
| Shares outstanding | 2.9M | 2.3M | 16.8M | 14.2M | 12.7M | 11.9M | 10.2M | 9.2M | 8.6M | 8.3M |
| Change in shares outstanding | +26.9% | −86.3% | +18.8% | +11.7% | +6.2% | +17.3% | +10.4% | +7.5% | +2.9% | +9.2% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −112.1% | −93.0% | −65.3% | −71.2% | −51.6% | −63.5% | −25.7% | −57.6% | −33.3% | −18.7% |
| Return on invested capital (ROIC) | −143.2% | −151.1% | −159.9% | −166.0% | −68.7% | −84.6% | −35.7% | −59.4% | −36.7% | −22.9% |
| Return on assets (ROA) | −59.4% | −65.4% | −50.4% | −55.3% | −39.1% | −51.2% | −20.8% | −45.7% | −28.6% | −16.9% |
| Return on tangible assets | −57.6% | −87.0% | −66.1% | −50.0% | −40.4% | −64.6% | −13.7% | −46.6% | −28.6% | −18.8% |
| Free cash flow margin | −76.8% | −73.0% | −101.1% | −104.0% | −3.4% | −77.1% | −66.0% | −46.4% | −23.4% | −14.1% |
| Financial health | ||||||||||
| Total debt | $2.4M | $458,000 | $785,000 | $1.1M | $1.4M | $1.6M | $1.8M | — | $0 | $0 |
| Cash & short-term investments | $1.3M | $2.4M | $4.2M | $9.7M | $5.9M | $4.2M | $8.6M | $686,785 | $1.2M | $1.2M |
| Net debt | $1.1M | −$1.9M | −$3.4M | −$8.6M | −$4.5M | −$2.6M | −$6.9M | −$686,785 | −$1.2M | −$1.2M |
| Debt / equity | 0.91 | 0.11 | 0.12 | 0.09 | 0.17 | 0.18 | 0.13 | — | 0.00 | 0.00 |
| Debt / assets | 0.35 | 0.08 | 0.08 | 0.07 | 0.12 | 0.14 | 0.10 | — | 0.00 | 0.00 |
| Current ratio | 1.62 | 2.80 | 3.51 | 6.58 | 4.69 | 7.10 | 10.00 | 3.56 | 5.00 | 7.96 |
| Quick ratio | 0.93 | 1.95 | 2.43 | 5.52 | 3.49 | 4.63 | 8.07 | 1.85 | 2.57 | 4.69 |
| Interest coverage | — | — | — | — | -170.2 | — | — | — | — | — |
| Working capital | $1.5M | $3.1M | $5.5M | $10.9M | $7.4M | $7.9M | $13.3M | $3.2M | $3.6M | $3.7M |
| Invested capital | $3.7M | $2.2M | $3.2M | $3.1M | $3.8M | $6.6M | $7.4M | $3.3M | $3.1M | $3.3M |
| Tangible asset value | $2.4M | $3.9M | $6.4M | $11.6M | $8.2M | $8.9M | $14.0M | $3.9M | $4.2M | $4.3M |
| Net current asset value | −$113,000 | $3.0M | $5.1M | $10.1M | $6.4M | $6.6M | $11.7M | $3.2M | $3.6M | $3.7M |
| Graham net-net per share | −$0.47 | $0.81 | $0.20 | $0.60 | $0.37 | $0.36 | $0.82 | $0.17 | $0.23 | $0.28 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | $0 | $0 |
| Share buybacks (net) | — | — | $0 | $705,000 | $85,000 | $165,919 | — | $0 | $0 | $0 |
| Capex / revenue | 0.0% | 0.7% | 2.1% | 1.5% | 0.9% | 4.1% | 1.8% | 3.3% | 2.3% | 1.7% |
| Capex / depreciation | 0.00 | 0.09 | 0.31 | 0.22 | 0.29 | 0.79 | 0.30 | 1.05 | 0.70 | 0.44 |
| Stock-based compensation / revenue | 10.7% | 8.7% | 15.5% | 22.2% | 6.7% | 18.8% | 3.0% | 2.9% | 0.3% | 0.4% |
| R&D / revenue | 17.7% | 19.3% | 27.5% | 29.7% | 9.6% | 30.5% | 28.5% | 32.3% | 25.1% | 19.5% |
| SG&A / revenue | 109.9% | 86.8% | 101.3% | 114.0% | 30.2% | 64.0% | 34.0% | 39.0% | 0.3% | 31.9% |
| Efficiency | ||||||||||
| Days sales outstanding | 62.1 | 57.7 | 56.2 | 51.1 | 21.6 | 81.7 | 87.8 | 79.1 | 61.0 | 64.0 |
| Days of inventory on hand | 142.6 | 146.6 | 168.4 | 166.8 | 64.6 | 161.8 | 185.9 | 202.2 | 187.2 | 173.9 |
| Days payables outstanding | 30.0 | 22.1 | 24.0 | 40.3 | 13.4 | 33.8 | 68.1 | 77.3 | 47.5 | 32.1 |
| Cash conversion cycle (days) | 174.8 | 182.1 | 200.6 | 177.6 | 72.7 | 209.7 | 205.6 | 204.0 | 200.7 | 205.8 |
| Receivables turnover | 5.87 | 6.33 | 6.49 | 7.14 | 16.93 | 4.47 | 4.16 | 4.61 | 5.98 | 5.71 |
| Payables turnover | 12.18 | 16.51 | 15.20 | 9.06 | 27.24 | 10.81 | 5.36 | 4.72 | 7.68 | 11.38 |
| Inventory turnover | 2.56 | 2.49 | 2.17 | 2.19 | 5.65 | 2.26 | 1.96 | 1.81 | 1.95 | 2.10 |
| Asset turnover | 0.70 | 0.70 | 0.46 | 0.41 | 1.63 | 0.50 | 0.59 | 0.99 | 1.09 | 1.08 |
| Average receivables | $758,000 | $839,000 | $834,500 | $747,909 | $1.1M | $1.6M | $1.6M | $1.1M | $929,976 | $1.0M |
| Average payables | $336,000 | $291,500 | $316,000 | $540,000 | $583,500 | $632,206 | $916,502 | $827,596 | $496,014 | $331,207 |
| Average inventory | $1.6M | $1.9M | $2.2M | $2.2M | $2.8M | $3.0M | $2.5M | $2.2M | $2.0M | $1.8M |
| Intangibles / total assets | 3.1% | 3.8% | 2.3% | 1.1% | 1.5% | 2.5% | 1.0% | 2.0% | 1.9% | 3.5% |
Computed from BMRA's annual financial statements (latest annual report filed August 31, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
BMRA valuation and financial ratios
Biomerica earned a return on equity of −112.1% and a return on invested capital of −143.2% in fiscal 2026. It ended the year with $2.4 million of debt and $1.3 million in cash and short-term investments, net debt of $1.1 million. The share count fell 65.0% from 8.3M to 2.9M over 9 years.
See the BMRA income statement, the BMRA chart for price history, or the BMRA stock overview for the latest quote and news.
BMRA key metrics FAQ
What is Biomerica's return on equity?
Biomerica's return on equity (ROE) was −112.1% in fiscal 2026: net income of -$3.8 million on average shareholders' equity of $3.4 million.
What is Biomerica's ROIC?
Biomerica's return on invested capital was −143.2% in fiscal 2026, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Biomerica have?
Biomerica had total debt of $2.4 million at the end of fiscal 2026, a debt-to-equity ratio of 0.91.
What is Biomerica's free cash flow yield?
Biomerica generated -$3.4 million of free cash flow in fiscal 2026, a free cash flow yield of −49.1% on its market value at year-end ($7.0 million).
What is Biomerica's current ratio?
Biomerica's current ratio was 1.62 at the end of fiscal 2026: current assets were 1.62 times current liabilities.